Mi az a Ozempic (Semaglutide)?
Ozempic (semaglutide) is a once-weekly injectable prescription medicine that belongs to the GLP-1 receptor agonist class. It is approved by the European Medicines Agency (EMA) for the treatment of type 2 diabetes in adults and is also used off-label by doctors for weight management in eligible patients.
Hogyan hat a Ozempic (Semaglutide)?
Ozempic works by mimicking the action of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone released by the gut after eating. When semaglutide binds to GLP-1 receptors throughout the body, it triggers several clinically significant responses:
- Appetite suppression: Signals in the brain’s hypothalamus reduce hunger and increase feelings of fullness (satiety), leading to reduced caloric intake.
- Slowed gastric emptying: Food moves more slowly from the stomach to the small intestine, prolonging the sensation of fullness after meals.
- Blood glucose regulation: Semaglutide stimulates insulin release from the pancreas in response to food and suppresses the release of glucagon, a hormone that raises blood sugar levels.
- Cardiovascular effects: Clinical data published by the EMA indicates that semaglutide reduces the risk of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.
Because the GLP-1 receptors targeted by semaglutide are distributed across multiple organ systems — including the brain, gut, heart, and pancreas — Ozempic’s effects extend beyond blood sugar control to include meaningful body weight reduction.
Kinek ajánlott a Ozempic (Semaglutide)?
Ozempic is indicated for adults with type 2 diabetes mellitus when diet and exercise alone are insufficient to achieve adequate glycaemic control. In clinical practice, independent doctors may also consider prescribing semaglutide off-label for weight management in adults who meet specific eligibility criteria, typically including:
- A body mass index (BMI) of 30 or above, or
- A BMI of 27 or above with at least one weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea
Ozempic is not appropriate for everyone. It is not recommended for people with a personal or family history of medullary thyroid carcinoma (MTC), people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or those who are pregnant or planning to become pregnant. A full medical assessment by a qualified doctor is required before any prescription can be issued.
Adagolás
Ozempic is administered once weekly by subcutaneous injection (under the skin of the abdomen, thigh, or upper arm). The standard titration schedule, as per EMA-approved prescribing guidance, is:
| Phase | Dose | Duration |
|---|---|---|
| Starting dose | 0.25 mg once weekly | 4 weeks |
| Maintenance step 1 | 0.5 mg once weekly | At least 4 weeks |
| Maintenance step 2 (if needed) | 1 mg once weekly | Ongoing or as directed |
| Maximum dose | 2 mg once weekly | As clinically indicated |
The starting dose of 0.25 mg is used to minimise gastrointestinal side effects during the initial weeks of treatment. Dose escalation should only occur under a doctor’s supervision. Patients should not adjust their dose without consulting their prescribing doctor.
Ozempic is available as a pre-filled injection pen. Injections can be given at any time of day, with or without food.
Mellékhatások
As with all medicines, Ozempic may cause side effects. Not all patients experience them, and many resolve as the body adapts to the medication.
Gyakori mellékhatások (10-ből több mint 1 személynél fordulhatnak elő)
- Nausea
- Diarrhoea
- Vomiting
- Constipation
- Abdominal pain or discomfort
These gastrointestinal effects are most common during the first weeks of treatment and typically become less severe over time. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated may help manage them.
Kevésbé gyakori, de súlyos mellékhatások
- Pancreatitis: Persistent severe abdominal pain that may radiate to the back. Stop treatment and seek immediate medical attention if this occurs.
- Gallbladder problems: Including gallstones (cholelithiasis) and cholecystitis. Report any upper-right abdominal pain, fever, or jaundice to a doctor promptly.
- Diabetic retinopathy complications: Reported in patients with pre-existing diabetic eye disease. Regular eye examinations are recommended.
- Hypoglycaemia: Risk is increased when semaglutide is used in combination with insulin or sulphonylureas.
- Acute kidney injury: Typically secondary to dehydration caused by gastrointestinal side effects.
- Allergic reactions: Serious allergic reactions, including anaphylaxis, have been reported rarely.
This is not a complete list of side effects. Refer to the EMA-approved product information for full prescribing details.
Ozempic (Semaglutide) vs alternatívák
Several GLP-1 receptor agonists and weight management medicines are available in Europe. The table below provides a factual comparison for informational purposes only. A doctor must assess which, if any, of these medicines is appropriate for an individual patient.
| Medicine | Active Ingredient | Form | Typical Dose | Approved Indication |
|---|---|---|---|---|
| Ozempic | Semaglutide | Weekly injection | 0.5–2 mg/week | Type 2 diabetes (EU) |
| Wegovy | Semaglutide | Weekly injection | Up to 2.4 mg/week | Weight management (EU) |
| Saxenda | Liraglutide | Daily injection | Up to 3 mg/day | Weight management (EU) |
Főbb különbségek:
- Ozempic vs Wegovy: Both contain semaglutide. Ozempic carries an EMA approval for type 2 diabetes at doses up to 2 mg. Wegovy is approved specifically for chronic weight management at a higher maximum dose of 2.4 mg. Clinical evidence supports greater average weight loss at the higher Wegovy dose.
- Ozempic vs Saxenda: Saxenda contains liraglutide, a different GLP-1 agonist that requires daily (rather than weekly) injections. Clinical head-to-head data indicates semaglutide (Ozempic/Wegovy) produces greater mean weight loss than liraglutide (Saxenda) over comparable treatment periods, per published clinical trial data referenced by the EMA.
Hogyan szerezhető be a Ozempic (Semaglutide) online Európában
Ozempic vényköteles gyógyszer az EU összes tagállamában. Nem adható ki jogszerűen érvényes orvosi rendelvény nélkül.
A Prescrivia technológiai közvetítőként működik: nem írunk fel gyógyszereket, nem alkalmazunk orvosokat és nem értékesítünk gyógyszereket. Platformunk pácienseket kapcsol össze független, EU-ban regisztrált orvosokkal, akik bizalmas online egészségügyi felméréseket végezhetnek.
A folyamat a következő:
- Töltse ki az egészségügyi kérdőívet: Answer a structured set of health questions designed to capture relevant medical history, current medications, and treatment goals. This assessment is reviewed by an independent doctor.
- Orvosi felülvizsgálat: An independent EU-registered doctor reviews your assessment. If semaglutide is clinically appropriate for you, they may issue a prescription. If it is not appropriate, the doctor will explain why.
- Recept és teljesítés: If a prescription is issued, it is sent to a licensed EU pharmacy partner. The pharmacy dispenses and ships the medicine directly to you.
Fontos: A Prescrivia nem garantálja a recept kiállítását. Minden felírási döntést független, képzett orvosok hoznak az Ön egyéni klinikai körülményei alapján.
Fontos biztonsági tudnivalók
Ne használja a Ozempic (Semaglutide) készítményt, ha:
- Have a personal or family history of medullary thyroid carcinoma (MTC)
- Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Are allergic to semaglutide or any other ingredient in Ozempic
- Are pregnant, planning to become pregnant, or breastfeeding
Tájékoztassa orvosát a Ozempic (Semaglutide) megkezdése előtt, ha:
- A history of pancreatitis
- Diabetic retinopathy
- Kidney disease
- Liver disease
- Gallbladder disease
- A history of eating disorders
Gyógyszer-kölcsönhatások: Ozempic may interact with other medications, particularly insulin and sulphonylureas (risk of hypoglycaemia), and oral contraceptives (potential reduced absorption due to delayed gastric emptying). Always disclose all current medications to your doctor during the assessment.
Ozempic is not a substitute for lifestyle changes. Dietary modification and regular physical activity remain important components of any weight management or diabetes treatment plan.
Források
Az oldalon található orvosi információk az alábbi forrásokon alapulnak:
- European Medicines Agency (EMA). Ozempic (semaglutide) — Summary of Product Characteristics. Available at: ema.europa.eu
- European Medicines Agency (EMA). Assessment report: Ozempic. EMEA/H/C/004174.
- World Health Organization (WHO). Obesity and overweight — Fact sheet. who.int
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
Ez a tartalom rendszeresen felülvizsgálatra kerül a frissített klinikai irányelvek tükrözése érdekében. Kizárólag tájékoztató jelleggel készült, és nem minősül orvosi tanácsadásnak. Mindig konzultáljon képzett egészségügyi szakemberrel az Ön egyéni egészségügyi körülményeire vonatkozó tanácsért.
Frequently asked questions
- Mire használják a Ozempic (Semaglutide)?
- Ozempic contains semaglutide and is primarily prescribed for type 2 diabetes management. It is also used off-label for weight management, though Wegovy (also semaglutide) is the version specifically approved for weight loss by the EMA.
- Milyen gyorsan does Ozempic work for weight loss?
- Most patients begin to notice weight loss within the first 4-8 weeks of treatment. Clinical trials showed an average weight reduction of 12-15% of body weight over 68 weeks of treatment.
- Megkaphatom a Ozempic (Semaglutide) készítményt online Európában?
- A készítményhez online közvetítő platformokon keresztül férhet hozzá, amelyek független, EU-ban regisztrált orvosokkal kötik össze Önt. A bizalmas egészségügyi kérdőív kitöltése után az orvos felméri, hogy a gyógyszer klinikailag megfelelő-e az Ön számára.
- Melyek a leggyakoribb mellékhatások?
- The most common side effects include nausea (particularly during the first few weeks), diarrhea, constipation, and abdominal pain. These typically diminish as the body adjusts to the medication.
- Mi a különbség Ozempic different from Wegovy?
- Both contain semaglutide, but Ozempic is approved for type 2 diabetes (doses up to 2mg) while Wegovy is approved specifically for weight management (dose up to 2.4mg). The active ingredient and mechanism are the same.
- Szükségem van receptre?
- Igen, ez a készítmény vényköteles gyógyszer az EU összes tagállamában. Képzett orvosnak kell felmérnie, hogy az Ön számára megfelelő-e, mielőtt receptet állít ki.
A Prescrivia közvetítő platform. Nem nyújtunk orvosi szolgáltatásokat, nem írunk fel kezeléseket és nem adunk ki gyógyszereket. Minden orvosi döntést független, EU-ban regisztrált orvosok hoznak. Minden gyógyszert engedéllyel rendelkező EU-gyógyszertárak adnak ki. Ez a platform összeköti a betegeket és az egészségügyi szolgáltatókat.